JLE

European Journal of Dermatology

MENU

Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases Volume 27, numéro 4, July-August 2017

Illustrations


  • Figure 1

  • Figure 2

Tableaux

Auteurs
1 University François Rabelais,
Boulevard Tonnelé,
37044 Tours Cedex 9,
France
2 Department of Dermatology,
Hospital of Orléans,
1 rue Porte Madeleine,
45032 Orléans,
France
3 Department of Dermatology,
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
4 Department of Pathology,
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
5 Department of Pathology,
Hospital of Orléans,
1 rue Porte Madeleine,
45032 Orléans,
France
6 International Agency for Research on Cancer,
Infections and Cancer Biology Group,
150 Cours Albert Thomas,
69372 Lyon CEDEX 08,
France
7 Laboratory “Biologie des Infections à Polyomavirus”,
ISP 1282,
INRA-University François,
Rabelais,
Tours,
France
* Reprints

Background

Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to systemic steroids.